Investigating how a protein called VAMP2 affects another protein linked to Parkinson's disease.
The role of VAMP2 in alpha-synuclein function and pathology
This study is looking at a protein called VAMP2 to see how it might help stop another protein linked to Parkinson's disease from clumping together, which could lead to new treatments for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Cincinnati NIH-funded |
| Lab location | 1 site (Cincinnati, United States) |
| Project ID | NIH-11047749 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of VAMP2, a protein that interacts with alpha-synuclein (α-Syn), which is associated with Parkinson's disease and Lewy body dementia. The study aims to explore how VAMP2 can prevent the aggregation of α-Syn, which is crucial for maintaining healthy neuron function. By examining the interactions between these proteins in both laboratory settings and animal models, the research seeks to uncover mechanisms that could lead to new therapeutic strategies for neurodegenerative diseases. The project will involve a combination of biochemical assays and in vivo experiments to assess the impact of VAMP2 on α-Syn's function and toxicity.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease or Lewy body dementia, particularly those with early onset symptoms.
Not a fit: Patients with other forms of dementia not linked to alpha-synuclein pathology may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that prevent or slow the progression of Parkinson's disease and related disorders.
How similar studies have performed: Previous research has shown promising results in understanding protein interactions in neurodegenerative diseases, suggesting that this approach could yield valuable insights.
Where this research is happening
Cincinnati, United States
- University of Cincinnati — Cincinnati, United States (Active)
Researchers
- Principal investigator: Diao, Jiajie — University of Cincinnati
- Study coordinator: Diao, Jiajie
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.